Back to top
more

Lantheus (LNTH)

(Delayed Data from NSDQ)

$112.50 USD

112.50
644,199

+0.54 (0.48%)

Updated Oct 16, 2024 04:00 PM ET

After-Market: $112.50 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (64 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

LabCorp Partners OmniSeq to Grow in Immuno-Oncology Space

LabCorp (LH) decides to distribute OmniSeq's molecular diagnostics assays in the United States and beyond to grow in immuno-oncology space.

    Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife

    Cerner's (CERN) growth in order bookings would continue to boost growth prospects. However, steep competition in the HCIT space raise concern.

      Quality Systems Professional Service a Drag, Competition Rife

      Quality Systems' (QSII) performance in the professional service business continues to be a drag in recent times. Also, macro headwinds continue to put pressure on performance.

        Here's Why You Must Add Chemed (CHE) Stock to Your Portfolio

        Chemed Corporation's (CHE) promising Roto-Rooter revenue outlook as well as an increased bottom-line guidance bode well of the company's future.

          BioScrip's Infusion Business Strong, Dull 2017 View a Drag

          BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.

            Here's Why Investors Should Buy BioTelemetry (BEAT) Now

            BioTelemetry's (BEAT) buyout of LifeWatch AG has expanded its product portfolio and customer base in the cardiac monitoring and diagnostic services space.

              Zimmer (ZBH) Plagued by Various Internal and External Issues

              Zimmer Biomet (ZBH) continues to suffer a bad patch, entangled with issues including its decade-old CEO's recent exit post a dull earnings season due to poor knee business.

                Myriad Genetics' EndoPredict Gets Positive Coverage Decision

                Considering Myriad Genetics' (MYGN) EndoPredict has been used clinically in more than 15,000 patients, we are confident about the growing adaptability of this test post the Medicare coverage approval.

                  Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics

                  Fluidigm (FLDM) has licensed rights to commercialize the cystic fibrosis transmembrane conductance regulator. The company is focused on improving its Juno automated microfluidic system.

                    Allscripts, Elligo Health Enter in Strategic Partnership

                    Allscripts' (MDRX) Strategic Partnership with Elligo Health would aid the company in capturing the Clinical Research Organizations' lucrative market.

                      Walgreens' (WBA) Research Website to Add Value in Healthcare

                      Walgreens Boots Alliance's (WBA) Center for Health & Wellbeing Research is set to improve patient care and outcomes while reducing health care costs at the same time.

                        Omnicell Upgrades Web Portal, Grows in Medication Management

                        Omnicell (OMCL) makes progress in medicare adherence with four new enhancements to its web portal PMAP.

                          Henry Schein to Offer CAEK's HIPAA Software LayerCompliance

                          Henry Schein (HSIC) inks an agreement to distribute CAEK's HIPAA related software, LayerCompliance.

                            Here's Why Investors Should Buy Edwards Lifesciences Now

                            Market is upbeat about Edwards Lifesciences's (EW) recent FDA approvals and strong 2017 guidance.

                              Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

                              IDEXX Laboratories (IDXX) rides high on strength across all segments, with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.

                                Here's Why Investors Should Buy Align Technology (ALGN) Now

                                Align Technology (ALGN) continues to ride high on robust growth in the Invisalign space.

                                  Intuitive Surgical at 52-Week High: What's Driving the Stock?

                                  Share price of Intuitive Surgical (ISRG) reaches a new 52-week high on the back of its new partnership and impressive second-quarter performance.

                                    Medtronic Announces RESOLUTE ONYX ONE-MONTH DAPT Study

                                    Medtronic (MDT) announces a clinical trial to evaluate one-month dual antiplatelet therapy in patients implanted with the Resolute Onyx Drug-Eluting Stent during PCI procedures.

                                      Zacks.com featured highlights: Coca-Cola FEMSA, Banco Bilbao Vizcaya Argentaria, Lantheus Holdings, Gilead Sciences and Lam Research

                                      Zacks.com featured highlights: Coca-Cola FEMSA, Banco Bilbao Vizcaya Argentaria, Lantheus Holdings, Gilead Sciences and Lam Research

                                        Cardiovascular Systems Unveils Favorable LIBERTY 360 Data

                                        LIBERTY 360 Study shows the importance of endovascular intervention in patients with Critical Limb Ischemia (CLI) to prevent amputation.

                                          5 Discounted PEG Stocks for GARP Investors

                                          PEG ratio is categorized under value investing and follows the principles of both growth and value investing.

                                            Lantheus Holdings at 52-Week High: What's Driving the Stock?

                                            Share price of Lantheus Holdings, Inc. (LNTH), based in North Billerica, U.S., scaled a new 52-week high of $17.85 on Jun 30, eventually closing a bit lower at $17.65.

                                              OraSure Technologies (OSUR) Catches Eye: Stock Jumps 10.1%

                                              OraSure Technologies, Inc. (OSUR) shares jumped a little above 10% in the last trading session.

                                                Why Investors Should Buy Align Technology (ALGN) Right Now

                                                Align Technology, Inc. (ALGN), the designer and manufacturer of Invisalign System, has rallied 51.9% over the last six months, ahead of the S&P 500's 7.9% gain.

                                                  Lantheus (LNTH) Scores a Strong Buy Right Now: Here's How

                                                  Lantheus Holdings, Inc. (LNTH) has rallied 28.2% over the last three months, ahead of the S&P 500's 4.3% gain.